Multiple functions of HuR in urinary tumors

  • Fa Zhang
  • Zhonglin Cai
  • Haidi Lv
  • Wenjuan Li
  • Mengtian Liang
  • Xupan Wei
  • Fenghai ZhouEmail author
Review – Cancer Research



Human embryonic lethal abnormal visual-like protein, HuR, belongs to a member of the Hu family of RNA-binding protein and plays a critical role in urinary tumors. The purpose of this review is to summarize the current literature to demonstrate the importance of HuR in urinary tract tumors’ biology and explore the potential role in therapeutic strategies aimed at targeting this molecule in cancer cells.


The relevant literature from PubMed and Medline databases is reviewed in this article.


Increasing evidence supports that HuR plays a critical role in urinary tumors’ biology because it regulates the expression of many urinary tumors-associated molecules through post-transcriptional regulatory mechanisms (including mRNA trafficking, mRNA decay and protein translation). Recent studies have demonstrated that HuR is associated with chemoresistance of urinary tumors, suggesting that HuR might be a novel therapeutic target and a marker for therapeutic response and prognosis assessment.


HuR is associated with various urinary tumors biological characteristics. Targeted therapy of HuR may become an attractive treatment strategy. What’s more, more preclinical and clinical trials of this targeted strategy are necessary for the treatment of urinary tumors.


ELAV1 HuR Urinary neoplasms Biological characteristics Chemotherapy resistance 



This study was funded by the Talent Innovation and Enterprise Program of Lanzhou (Grant no. 2015-RC-16).

Compliance with ethical standards

Conflict of interest

Authors have no conflicts of interest to declare.

Ethical approval

This article does not contain any studies with animals performed by any of the authors. This article does not contain any studies with human participants or animals performed by any of the authors.


  1. Abdelmohsen K, Kim MM, Srikantan S (2010) miR-519 suppresses tumor growth by reducing HuR levels. Cell Cycle 9(7):1354–1359CrossRefGoogle Scholar
  2. Annabi B, Bouzeghrane M, Currie JC (2006) Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling. Anticancer Drugs 17(4):429–438CrossRefGoogle Scholar
  3. Barbisan F, Mazzucchelli R, Santinelli A (2009) Overexpression of ELAV-like protein HuR is associated with increased COX-2 expression in atrophy, high-grade prostatic intraepithelial neoplasia, and incidental prostate cancer in cystoprostatectomies. Eur Urol 56(1):105–112CrossRefGoogle Scholar
  4. Basu A, Datta D, Zurakowski D (2010) Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development. J Biol Chem 13(33):25196–25202 285(CrossRefGoogle Scholar
  5. Brennan CM, Steitz JA (2001) HuR and mRNA stability. Cell Mol Life Sci 58(2):266–277CrossRefGoogle Scholar
  6. Carmeliet P (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology 69(Suppl 3):4–10CrossRefGoogle Scholar
  7. Cathomas R, De Santis M, Galsky MD (2015) First-line treatment of metastatic disease: cisplatin-ineligible patients. Hematol Oncol Clin N Am 29(2):329–340, xCrossRefGoogle Scholar
  8. Cha JD, Li S, Cha IH (2011) Association between expression of embryonic lethal abnormal vision-like protein HuR and cyclooxygenase-2 in oral squamous cell carcinoma. Head Neck 33(5):627–637CrossRefGoogle Scholar
  9. Chae KS, Kang MJ, Lee JH (2011) Opposite functions of HIF-α isoforms in VEGF induction by TGF-β1 under non-hypoxic conditions. Oncogene 30(10):1213–1228CrossRefGoogle Scholar
  10. Clark PE (2007) Recent advances in targeted therapy for renal cell carcinoma. Curr Opin Urol 17(5):331–336CrossRefGoogle Scholar
  11. Danilin S, Sourbier C, Thomas L (2009) von Hippel-Lindau tumor suppressor gene-dependent mRNA stabilization of the survival factor parathyroid hormone-related protein in human renal cell carcinoma by the RNA-binding protein HuR. Carcinogenesis 30(3):387–396CrossRefGoogle Scholar
  12. Danilin S, Sourbier C, Thomas L (2010) Role of the RNA-binding protein HuR in human renal cell carcinoma. Carcinogenesis 31(6):1018–1026CrossRefGoogle Scholar
  13. Datta K, Mondal S, Sinha S (2005) Role of elongin-binding domain of von Hippel Lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma. Oncogene 24(53):7850–7858CrossRefGoogle Scholar
  14. Denkert C, Weichert W, Winzer KJ (2004a) Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res 10(16):5580–5586CrossRefGoogle Scholar
  15. Denkert C, Weichert W, Pest S (2004b) Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res 64(1):189–195CrossRefGoogle Scholar
  16. Denkert C, Koch I, von Keyserlingk N et al (2006) Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Mod Pathol 19(9):1261–1269CrossRefGoogle Scholar
  17. Dufies M, Giuliano S, Ambrosetti D (2017) Sunitinib stimulates expression of VEGFC by tumor cells and promotes lymphangiogenesis in clear cell renal cell carcinomas. Cancer Res 77(5):1212–1226CrossRefGoogle Scholar
  18. Epis MR, Barker A, Giles KM (2011) The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells. J Biol Chem 286(48):41442–41454CrossRefGoogle Scholar
  19. Fay J, Kelehan P, Lambkin H (2009) Increased expression of cellular RNA-binding proteins in HPV-induced neoplasia and cervical cancer. J Med Virol 81(5):897–907CrossRefGoogle Scholar
  20. Filippova N, Yang X, Wang Y et al (2011) The RNA-binding protein HuR promotes glioma growth and treatment resistance. Mol Cancer Res 9(5):648–659CrossRefGoogle Scholar
  21. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y, Deguchi T, Ito M (2008) Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 377(1):114–119CrossRefGoogle Scholar
  22. Fus ŁP, Pihowicz P, Koperski Ł (2018) High cytoplasmic HuR expression is associated with advanced pT stage, high grade and increased microvessel density in urothelial bladder carcinoma. Ann Diagn Pathol 33:40–44CrossRefGoogle Scholar
  23. Guo J, Lv J, Chang S (2016) Inhibiting cytoplasmic accumulation of HuR synergizes genotoxic agents in urothelial carcinoma of the bladder. Oncotarget 7(29):45249–45262CrossRefGoogle Scholar
  24. Gupta S, Mahipal A (2013) Role of systemic chemotherapy in urothelial urinary bladder cancer. Cancer Control 20(3):200–210CrossRefGoogle Scholar
  25. Heinonen M, Bono P, Narko K (2005) Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res 65(6):2157–2161CrossRefGoogle Scholar
  26. Janakiraman H, House RP, Talwar S et al (2017) Repression of caspase-3 and RNA-binding protein HuR cleavage by cyclooxygenase-2 promotes drug resistance in oral squamous cell carcinoma. Oncogene 36(22):3137–3148CrossRefGoogle Scholar
  27. Jung-Hynes B, Nihal M, Zhong W, Ahmad N (2009) Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem 284(6):3823–3832CrossRefGoogle Scholar
  28. Kim KY, Li S, Cha JD et al (2012) Significance of molecular markers in survival prediction of oral squamous cell carcinoma. Head Neck 34(7):929–936CrossRefGoogle Scholar
  29. Kojima K, Fujita Y, Nozawa Y et al (2010) MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 70(14):1501–1512CrossRefGoogle Scholar
  30. Koljonen V, Böhling T, Haglund C (2008) Expression of HuR in Merkel cell carcinoma and in normal skin. J Cutan Pathol 35(1):10–14Google Scholar
  31. Kurosu T, Ohga N, Hida Y (2011) HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium. Br J Cancer 104(5):819–829CrossRefGoogle Scholar
  32. Latorre E, Tebaldi T, Viero G et al (2012) Downregulation of HuR as a new mechanism of doxorubicin resistance in breast cancer cells. Mol Cancer 11:13CrossRefGoogle Scholar
  33. Latorre E, Castiglioni I, Gatto P et al (2014) Loss of protein kinase Cδ/HuR interaction is necessary to doxorubicin resistance in breast cancer cell lines. J Pharmacol Exp Ther 349(1):99–106CrossRefGoogle Scholar
  34. Liang PI, Li WM, Wang YH (2012) HuR cytoplasmic expression is associated with increased cyclin A expression and poor outcome with upper urinary tract urothelial carcinoma. BMC Cancer 12:611CrossRefGoogle Scholar
  35. Lim SJ, Kim HJ, Kim JY (2007) Expression of HuR is associated with increased cyclooxygenase-2 expression in uterine cervical carcinoma. Int J Gynecol Pathol 26(3):229–234CrossRefGoogle Scholar
  36. Lin GL, Ting HJ, Tseng TC et al (2017) Modulation of the mRNA-binding protein HuR as a novel reversal mechanism of epirubicin-triggered multidrug resistance in colorectal cancer cells. PLoS ONE 12(10):e0185625CrossRefGoogle Scholar
  37. Liu H, Song X, Hou J et al (2018) Posttranscriptional regulation of human antigen R by miR-133b enhances docetaxel cytotoxicity through the inhibition of ATP-binding cassette subfamily G member 2 in prostate cancer cells. DNA Cell Biol 37(3):210–219CrossRefGoogle Scholar
  38. Long BJ, Grigoryev DN, Nnane IP (2000) Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Cancer Res 60(23):6630–6640Google Scholar
  39. Maeda T, Takahashi A, Hirobe M (2007) Adverse events of MVAC chemotherapy in patients with advanced urothelial cancer of the bladder. Hinyokika Kiyo 53(4):213–219Google Scholar
  40. Matsuo T, Miyata Y, Asai A (2017) Green tea polyphenol induces changes in cancer-related factors in an animal model of bladder cancer. PLoS One 12(1):e0171091CrossRefGoogle Scholar
  41. Mitsunari K, Miyata Y, Asai A (2016) Human antigen R is positively associated with malignant aggressiveness via upregulation of cell proliferation, migration, and vascular endothelial growth factors and cyclooxygenase-2 in prostate cancer. Transl Res 175:116–128CrossRefGoogle Scholar
  42. Miyata Y, Watanabe S, Sagara Y (2013) High expression of HuR in cytoplasm, but not nuclei, is associated with malignant aggressiveness and prognosis in bladder cancer. PLoS One 8(3):e59095CrossRefGoogle Scholar
  43. Miyata Y, Mitsunari K, Akihiro A (2017) Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer. Oncol Lett 13(2):811–818CrossRefGoogle Scholar
  44. Mrena J, Wiksten JP, Thiel A et al (2005) Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res 11(20):7362–7368CrossRefGoogle Scholar
  45. Nakano M, Shoji S, Higure T (2016) Low-dose docetaxel, estramustine and prednisolone combination chemotherapy for castration-resistant prostate cancer. Mol Clin Oncol 4(6):942–946CrossRefGoogle Scholar
  46. Niesporek S, Kristiansen G, Thoma A (2008) Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression. Int J Oncol 32(2):341–347Google Scholar
  47. Ning P, Zhong JG2, Jiang F (2016) Role of protein S in castration-resistant prostate cancer-like cells. Endocr Relat Cancer 23(8):595–607CrossRefGoogle Scholar
  48. Robinow S, Campos AR, Yao KM (1988) The elav gene product of Drosophila, required in neurons, has three RNP consensus motifs. Science 242(4885):1570–1572CrossRefGoogle Scholar
  49. Ronkainen H, Vaarala MH, Hirvikoski P, Ristimäki A (2011) HuR expression is a marker of poor prognosis in renal cell carcinoma. Tumour Biol 32(3):481–487CrossRefGoogle Scholar
  50. Roychowdhury S, Chinnaiyan AM (2013) Advancing precision medicine for prostate cancer through genomics. J Clin Oncol 31(15):1866–1873CrossRefGoogle Scholar
  51. Sahin M, Sahin E, Gümüslü S (2009) Cyclooxygenase-2 in cancer and angiogenesis. Angiology 60(2):242–253CrossRefGoogle Scholar
  52. Siegel R, Naishadham D, Jemal A. Cancer statistics (2013) CA Cancer J Clin 63(1):11–30CrossRefGoogle Scholar
  53. Siegel RL, Miller KD, Jemal A. Cancer statistics (2015) CA Cancer J Clin 65(1):5–29CrossRefGoogle Scholar
  54. Sourbier C, Massfelder T (2006) Parathyroid hormone-related protein in human renal cell carcinoma. Cancer Lett 240(2):170–182CrossRefGoogle Scholar
  55. To KK, Leung WW, Ng SS (2015) Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. Exp Cell Res 338(2):222–231CrossRefGoogle Scholar
  56. von Roretz C, Di Marco S, Mazroui R (2011) Turnover of AU-rich-containing mRNAs during stress: a matter of survival. Wiley Interdiscip Rev RNA 2(3):336–347CrossRefGoogle Scholar
  57. Wang J, Zhao W, Guo Y et al (2009) The expression of RNA-binding protein HuR in non-small cell lung cancer correlates with vascular endothelial growth factor-C expression and lymph node metastasis. Oncology 76(6):420–429CrossRefGoogle Scholar
  58. Wang Y, Wang X, Zhao H et al (2012) Clusterin confers resistance to TNF -alpha -induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression. J Chemotherapy 24(24):348–357CrossRefGoogle Scholar
  59. Wang J, Guo Y, Chu H et al (2013) Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis. Int J Mol Sci 14(5):10015–10041CrossRefGoogle Scholar
  60. Wenger RH, Stiehl DP, Camenisch G (2005) Integration of oxygen signaling at the consensus HRE. Sci STKE 2005(306):re12Google Scholar
  61. Xin H, Brown JA, Gong C (2012) Association of the von Hippel-Lindau protein with AUF1 and posttranscriptional regulation of VEGFA mRNA. Mol Cancer Res 10(1):108–120CrossRefGoogle Scholar
  62. Yeap BB, Voon DC, Vivian JP (2002) Novel binding of HuR and poly(C)-binding protein to a conserved UC-rich motif within the 3′-untranslated region of the androgen receptor messenger RNA. J Biol Chem 277(30):27183–27192CrossRefGoogle Scholar
  63. Yoo PS, Mulkeen AL, Cha CH (2006) Post-transcriptional regulation of vascular endothelial growth factor: implications for tumor angiogenesis. World J Gastroenterol 12(31):4937–4942CrossRefGoogle Scholar
  64. Yu D, Zhang C, Gui J (2017) RNA-binding protein HuR promotes bladder cancer progression by competitively binding to the long noncoding HOTAIR with miR-1. Onco Targets Ther 10:2609–2619CrossRefGoogle Scholar
  65. Zhang YK, Zhang GN, Wang YJ et al (2016) Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters. Sci Rep 6:25694CrossRefGoogle Scholar
  66. Zhou Y, Chang R, Ji W et al (2016) Loss of scribble promotes snail translation through translocation of HuR and enhances cancer drug resistance. J Biol Chem 291(1):291–302CrossRefGoogle Scholar
  67. Zhu Z, Wang B, Bi J (2013) Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and poor outcome in breast cancer. Tumour Biol 34(4):2299–2308CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of UrologyGansu Provincial HospitalLanzhouChina
  2. 2.Department of Urology, Peking Union Medical College Hospital, Peking Union Medical CollegeChinese Academy of Medical SciencesBeijingChina

Personalised recommendations